Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

View the 50 largest pharmaceutical companies in the world listings here

Kyowa Kirin in the Drug Discovery & Development Pharma 50

Kyowa Kirin

Rank: 49

2021 Rank: na

Tokyo, Japan
www.kyowakirin.com

2021 Revenues ($USD) : $3,206,900,947
2021 Revenues (foreign currencies) : JP¥352,246,000,000
2021 R&D spend : $525,118,354
2021 Number of Employees : 5,752
Fiscal Year End : 12/31/2021
Leader : CEO Masashi Miyamoto

Kyowa Kirin

[Image courtesy of Kyowa Kirin]

The Tokyo-headquartered pharmaceutical and biotechnology firm focuses on developing drugs in oncology, nephrology, central nervous system and immunology. Focus areas for its drug discovery efforts include therapeutic antibodies, small molecule drugs, nucleic acid drugs and regenerative medicine. Central products include anemia treatments ESPO and Nesp — as well as G-Lasta, a sustained duration form of granulocyte colony-stimulating factor product of chemotherapy-induced neutropenia. —BB

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50